Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL.

Ghorashian S, Amrolia P, Veys P.

Exp Hematol. 2018 Oct;66:5-16. doi: 10.1016/j.exphem.2018.07.002. Epub 2018 Jul 20. Review.

PMID:
30031849
2.

Redirection to the bone marrow improves T cell persistence and antitumor functions.

Khan AB, Carpenter B, Santos E Sousa P, Pospori C, Khorshed R, Griffin J, Velica P, Zech M, Ghorashian S, Forrest C, Thomas S, Gonzalez Anton S, Ahmadi M, Holler A, Flutter B, Ramirez-Ortiz Z, Means TK, Bennett CL, Stauss H, Morris E, Lo Celso C, Chakraverty R.

J Clin Invest. 2018 May 1;128(5):2010-2024. doi: 10.1172/JCI97454. Epub 2018 Apr 9.

3.

A guide to manufacturing CAR T cell therapies.

Vormittag P, Gunn R, Ghorashian S, Veraitch FS.

Curr Opin Biotechnol. 2018 Oct;53:164-181. doi: 10.1016/j.copbio.2018.01.025. Epub 2018 Feb 18. Review.

PMID:
29462761
4.

Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia.

Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, Clifton-Hadley L, Champion K, Sattar Z, Popova B, Hackshaw A, Smith P, Roberts T, Biagi E, Dreno B, Rousseau R, Kailayangiri S, Ahlmann M, Hough R, Kremens B, Sauer MG, Veys P, Goulden N, Cummins M, Amrolia PJ.

Leukemia. 2017 May;31(5):1087-1095. doi: 10.1038/leu.2017.39. Epub 2017 Jan 27.

PMID:
28126984
5.

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells.

Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S, Pinner D, Ahsan G, Gilmour K, Lucchini G, Inglott S, Mifsud W, Chiesa R, Peggs KS, Chan L, Farzeneh F, Thrasher AJ, Vora A, Pule M, Veys P.

Sci Transl Med. 2017 Jan 25;9(374). pii: eaaj2013. doi: 10.1126/scitranslmed.aaj2013. Erratum in: Sci Transl Med. 2017 Feb 15;9(377):null.

PMID:
28123068
6.

Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy.

Holler A, Zech M, Ghorashian S, Pike R, Hotblack A, Veliça P, Xue SA, Chakraverty R, Morris EC, Stauss HJ.

Haematologica. 2016 Apr;101(4):482-90. doi: 10.3324/haematol.2015.132712. Epub 2016 Jan 22.

7.

CD19 chimeric antigen receptor T cell therapy for haematological malignancies.

Ghorashian S, Pule M, Amrolia P.

Br J Haematol. 2015 May;169(4):463-78. doi: 10.1111/bjh.13340. Epub 2015 Mar 5. Review.

PMID:
25753571
8.

CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.

Ghorashian S, Veliça P, Chua I, McNicol AM, Carpenter B, Holler A, Nicholson E, Ahmadi M, Zech M, Xue SA, Uckert W, Morris E, Chakraverty R, Stauss HJ.

J Immunol. 2015 Feb 1;194(3):1080-9. doi: 10.4049/jimmunol.1401703. Epub 2014 Dec 24.

9.

OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence.

Buchan S, Manzo T, Flutter B, Rogel A, Edwards N, Zhang L, Sivakumaran S, Ghorashian S, Carpenter B, Bennett C, Freeman GJ, Sykes M, Croft M, Al-Shamkhani A, Chakraverty R.

J Immunol. 2015 Jan 1;194(1):125-133. doi: 10.4049/jimmunol.1401644. Epub 2014 Nov 17.

10.

The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom.

Cabrita IZ, Mohammed A, Layton M, Ghorashian S, Gilmore A, Cho G, Howard J, Anie KA, Desforges L, Bassett P, Grapsa J, Howard L, Mahalingam G, Dawson D, Pinto FJ, Nihoyannopoulos P, Davies SC, Gibbs JS.

Br J Haematol. 2013 Aug;162(3):400-8. doi: 10.1111/bjh.12391. Epub 2013 May 29.

PMID:
23713628
11.

Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo.

Xue SA, Gao L, Ahmadi M, Ghorashian S, Barros RD, Pospori C, Holler A, Wright G, Thomas S, Topp M, Morris EC, Stauss HJ.

Oncoimmunology. 2013 Jan 1;2(1):e22590.

12.

Improving TCR Gene Therapy for Treatment of Haematological Malignancies.

Nicholson E, Ghorashian S, Stauss H.

Adv Hematol. 2012;2012:404081. doi: 10.1155/2012/404081. Epub 2012 Jan 26.

13.

T cell gene-engineering to enhance GVT and suppress GVHD.

Ghorashian S, Nicholson E, Stauss HJ.

Best Pract Res Clin Haematol. 2011 Sep;24(3):421-33. doi: 10.1016/j.beha.2011.05.004. Epub 2011 Jun 28. Review.

PMID:
21925095
14.

Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation.

Flutter B, Edwards N, Fallah-Arani F, Henderson S, Chai JG, Sivakumaran S, Ghorashian S, Bennett CL, Freeman GJ, Sykes M, Chakraverty R.

J Clin Invest. 2010 Nov;120(11):3855-68. doi: 10.1172/JCI41446. Epub 2010 Oct 18.

15.

Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.

Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, Kande V.

Lancet. 2009 Jul 4;374(9683):56-64. doi: 10.1016/S0140-6736(09)61117-X. Epub 2009 Jun 24.

PMID:
19559476
16.

Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.

Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Karunakara U.

Clin Infect Dis. 2007 Dec 1;45(11):1435-42. Epub 2007 Oct 22.

PMID:
17990225
17.

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.

Khorashad JS, Milojkovic D, Mehta P, Anand M, Ghorashian S, Reid AG, De Melo V, Babb A, de Lavallade H, Olavarria E, Marin D, Goldman JM, Apperley JF, Kaeda JS.

Blood. 2008 Feb 15;111(4):2378-81. Epub 2007 Nov 2.

18.

Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo.

Balasegaram M, Harris S, Checchi F, Ghorashian S, Hamel C, Karunakara U.

Bull World Health Organ. 2006 Oct;84(10):783-91.

19.

"Off-license" use of recombinant activated factor VII.

Ghorashian S, Hunt BJ.

Blood Rev. 2004 Dec;18(4):245-59. Review.

PMID:
15501553

Supplemental Content

Loading ...
Support Center